Springer Protocols: Abstract: 23. Antibody-Cytokine Fusion Proteins for the Therapy of Cancer

23. Antibody-Cytokine Fusion Proteins for the Therapy of Cancer

By: Gustavo Helguera³, Manuel L. Penichet³

Abstract

Full Text

Download PDF (406K)

In recent years the development of tumor-specific recombinant antibodies fused to immunostimulatory cytokines such as interleukin-2 (IL-2), interleukin-12 (IL-12), and granulocyte/mac rophage colony-stimulating factor (GM-CSF) has provided a promising novel approach to cancer immunotherapy. The combined properties of specific targeting of antibodies and the immune stimulation of cytokines results in high cytokine concentration in the tumor microenvironment, and as a consequence, in an improved tumoricidal activity of the antibody and/or in a secondary effective immune response against the tumor. In the present chapter we describe strategies for the construction, expression, and in vitro characterization of antibody-cytokine fusion proteins, with particular emphasis on antibody/IL-2 fusion proteins.

Affiliation(s): (3) Department of Microbiology, Immunology, and Molecular Genetics, and the Molecular Biology Institute, University of California, Los Angeles, CA

Book Title: Adoptive Immunotherapy: Methods and Protocols

Series: Methods in Molecular Medicine | Volume: 109 | Pub. Date: Nov-30-2004 | Page Range: 347-373 | DOI: 10.1385/1-59259-862-5:347

Subject: Immunology

Key Words: Antibody engineering - antibody therapy - antibody - cancer - constant region - cytokine - expression vector fusion protein - IgG3 - HER2/neu - immunocytokine - immunoglobu-lin - immunoligand - immunotherapy - interleukin-2 - tumor targeting - variable region

References

Download References

1.	Lode, H. N., Xiang, R., Becker, J. C., Gillies, S. D., and Reisfeld, R. A. (1998) Immunocytokines: a promising approach to cancer immunotherapy. Pharmacol. Ther. 80, 277–292.

2.	Helguera, G., Morrison, S. L., and Penichet, M. L. (2002) Antibody-cytokine fusion proteins: harnessing the combined power of cytokines and antibodies for cancer therapy. Clin. Immunol. 105, 233–246.

3.	Penichet, M. L., Shin, S. U., and Morrison, S. L. (1999) Fab fusion proteins: Immuno-ligands. In: Antibody Fusion Proteins. Chamow, S. M. and Ashkenazi, A., eds. John Wiley & Son, New York, NY, pp. 15–52.

4.	Liu, S. J., Sher, Y. P., Ting, C. C., Liao, K. W., Yu, C. P., and Tao, M. H. (1998) Treatment of B-cell lymphoma with chimeric IgG and single-chain Fv antibody-interleukin-2 fusion proteins. Blood 92, 2103–2112.

5.	Hornick, J. L., Khawli, L. A., Hu, P., Lynch, M., Anderson, P. M., and Epstein, A. L. (1997) Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties. Blood 89, 4437–4447.

6.	Dela Cruz, J. S., Lau, S. Y., Ramirez, E. M., et al. (2003) Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice. Vaccine 21, 1317–1326.

7.	Penichet, M. L., Harvill, E. T., and Morrison, S. L. (1998) An IgG3-IL-2 fusion protein recognizing a murine B cell lymphoma exhibits effective tumor imaging and antitumor activity. J. Interferon Cytokine Res. 18, 597–607.

8.	Becker, J. C., Pancook, J. D., Gillies, S. D., Furukawa, K., and Reisfeld, R. A. (1996) T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J. Exp. Med. 183, 2361–2366.

9.	Becker, J. C., Varki, N., Gillies, S. D., Furukawa, K., and Reisfeld, R. A. (1996) Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. J. Clin. Invest. 98, 2801–2804.

10.	Xiang, R., Lode, H. N., Dolman, C. S., et al. (1997) Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Cancer Res. 57,4948–4955.

11.	Hank, J. A. A. M., Gan, J., Sternberg, A., et al. (2003) Clinical Administration of anti-body-cytokine hu14.18-IL-2 induces IL-2-mediated immune activation. In: Proceedings of the American Association for Cancer Research, 94th Annual Meeting. 2nd Ed., Vol. 44, Washington, DC, p. 1156.

12.	Janeway, C. A., Travers, P., Walport, M., and Schlomchick, M. (2001) Immunobiology: the Immune System in Health and Disease. 5th Ed. Garland, New York, NY.

13.	Gillies, S. D., Reilly, E. B., Lo, K. M., and Reisfeld, R. A. (1992) Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc. Natl. Acad. Sci. USA 89, 1428–1432.

14.	Harvill, E. T. and Morrison, S. L. (1995) An IgG3-IL2 fusion protein activates complement, binds Fc gamma RI, generates LAK activity and shows enhanced binding to the high affinity IL2-R. Immunotechnology 1, 95–105.

15.	Brambell, F. W., Hemmings, W. A., and Morris, I. G. (1964) A theoretical model of gamma-globulin catabolism. Nature 203, 1352–1354.

16.	Ward, E. S., Zhou, J., Ghetie, V., and Ober, R. J. (2003) Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans. Int. Immunol. 15, 187–195.

17.	Challita-Eid, P. M., Abboud, C. N., Morrison, S. L., et al. (1998) A RANTES-antibody fusion protein retains antigen specificity and chemokine function. J. Immunol. 161, 3729–3736.

18.	McGrath, J. P., Cao, X., Schutz, A., et al. (1997) Bifunctional fusion between nerve growth factor and a transferrin receptor antibody. J. Neurosci. Res. 47, 123–133.

19.	Peng, L. S., Penichet, M. L., and Morrison, S. L. (1999) A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity. J. Immunol. 163, 250–258.

20.	Lustgarten, J., Marks, J., and Sherman, L. A. (1999) Redirecting effector T cells through their IL-2 receptors. J. Immunol. 162, 359–365.

21.	Halin, C., Gafner, V., Villani, M. E., et al. (2003) Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res. 63, 3202–3210.

22.	Moreland, L. W., Baumgartner, S. W., Schiff, M. H., et al. (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337, 141–147.

23.	Moreland, L. W., Schiff, M. H., Baumgartner, S. W., et al. (1999) Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med. 130, 478–486.

24.	Verma, R., Boleti, E., and George, A. J. (1998) Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems. J. Immunol. Methods 216, 165–181.

25.	Potter, K. N., Li, Y., and Capra, J. D. (1993) Antibody production in the baculovirus expression system. Int. Rev. Immunol. 10, 103–112.

26.	Yoo, E. M., Chintalacharuvu, K. R., Penichet, M. L., and Morrison, S. L. (2002) Myeloma expression systems. J. Immunol. Methods 261, 1–20.

27.	Wright, A., Shin, S. U., and Morrison, S. L. (1992) Genetically engineered antibodies: progress and prospects. Crit. Rev. Immunol. 12, 125–168.

28.	Penichet, M. L., Dela Cruz, J. S., Shin, S. U., and Morrison, S. L. (2001) A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors. Hum. Antibodies 10, 43–49.

29.	Shin, S. U., Friden, P., Moran, M., and Morrison, S. L. (1994) Functional properties of antibody insulin-like growth factor fusion proteins. J. Biol. Chem. 269, 4979–4985.

30.	Harlow, E. and Lane, D. (1989) Anti-immunoglobulin antibodies. In: Antibodies: A Laboratory Manual. 1st Ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, pp. 623–631.

31.	Penichet, M. L., Dela Cruz, J. S., Challita-Eid, P. M., Rosenblatt, J. D., and Morrison, S. L. (2001) A murine B cell lymphoma expressing human HER2 / neu undergoes spontaneous tumor regression and elicits antitumor immunity. Cancer Immunol. Immunother. 49, 649–662.

32.	Morrison, S. L. (1994) Cloning, expression, and modification of antibody V regions. In: Current Protocols in Immunology, Vol. 1. Coligan, J. E., Kruisbeek, A. M., Margulies, D. H., Shevach, E. M., and Strober, W., eds. John Wiley & Sons, New York, NY, pp. 2.12.1–2.12.16.

33.	Shin, S. U. and Morrison, S. L. (1990) Expression and characterization of an antibody binding specificity joined to insulin-like growth factor 1: potential applications for cellular targeting. Proc. Natl. Acad. Sci. USA 87, 5322–5326.

34.	Coloma, M. J., Hastings, A., Wims, L. A., and Morrison, S. L. (1992) Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. J. Immunol. Methods. 152, 89–104.

35.	Norderhaug, L., Olafsen, T., Michaelsen, T. E., and Sandlie, I. (1997) Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells. J. Immunol. Methods 204, 77–87.

36.	Preston, M. J., Gerceker, A. A., Reff, M. E., and Pier, G. B. (1998) Production and characterization of a set of mouse-human chimeric immunoglobulin G (IgG) subclass and IgA monoclonal antibodies with identical variable regions specific for Pseudomo-nas aeruginosa serogroup O6 lipopolysaccharide. Infect. Immun. 66, 4137–4412.

37.	Larrick, J. W., Danielsson, L., Brenner, C. A., Abrahamson, M., Fry, K. E., and Borrebaeck, C. A. (1989) Rapid cloning of rearranged immunoglobulin genes from human hybridoma cells using mixed primers and the polymerase chain reaction. Biochem. Biophys. Res. Commun. 160, 1250–1256.

38.	Powers, D. B. and Marks, J. (1999) Monovalent phage display of Fab and scFv fusions. In: Antibody Fusion Proteins. Chamow, S. M. and Ashkenazi, A., eds. John Wiley & Son, New York, NY, pp. 151–188.

39.	Carter, P., Presta, L., Gorman, C. M., et al. (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA 89,4285–4289.

40.	Mulligan, R. C. and Berg, P. (1981) Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase. Proc. Natl. Acad. Sci. USA 78, 2072–2076.

41.	Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Subcloning. In: Molecular Cloning: A Laboratory Manual. 2nd. Ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. F.1–F.11.

42.	Southern, P. J. and Berg, P. (1982) Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. J. Mol. Appl. Genet. 1,327–341.

43.	Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Analysis and cloning of eukaryotic genomic DNA. In: Molecular Cloning: A Laboratory Manual. 2nd Ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 9.1–9.62.

44.	Challita-Eid, P. M., Penichet, M. L., Shin, S. U., et al. (1998) A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway. J. Immunol. 160, 3419–3426.

45.	Dela Cruz, J. S., Trinh, K. R., Morrison, S. L., and Penichet, M. L. (2000) Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity. J. Immunol. 165, 5112–5121.

46.	Penichet, M. L., Challita, P. M., Shin, S. U., Sampogna, S. L., Rosenblatt, J. D., and Morrison, S. L. (1999) In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice. Lab. Anim. Sci. 49, 179–188.

47.	Deans, R. J., Denis, K. A., Taylor, A., and Wall, R. (1984) Expression of an immunoglobulin heavy chain gene transfected into lymphocytes. Proc. Natl. Acad. Sci. USA 81, 1292–1296.

48.	Foecking, M. K. and Hofstetter, H. (1986) Powerful and versatile enhancer-promoter unit for mammalian expression vectors. Gene 45, 101–105.

49.	McLean, G. R., Nakouzi, A., Casadevall, A., and Green, N. S. (2000) Human and murine immunoglobulin expression vector cassettes. Mol. Immunol. 37, 837–845.

50.	Harlow, E. and Lane, D. (1989) Electrophoresis. In: Antibodies: A Laboratory Manual. 1st Ed., pp. 635–658.

51.	Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Commonly Used Techniques in Molecular Cloning. In: Molecular Cloning: A Laboratory Manual. 2nd Ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, pp. E.1–E.39.

52.	Harlow, E. and Lane, D. (1989) Storing and purifying antibodies. In: Antibodies: A Laboratory Manual. 1st Ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, pp. 285–318.

53.	Harlow, E. and Lane, D. (1989) Immunoaffinity purification. In: Antibodies: A Laboratory Manual. 1st Ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, pp. 511–551.

54.	Meininger, D. P., Rance, M., Starovasnik, M. A., Fairbrother, W. J., and Skelton, N. J. (2000) Characterization of the binding interface between the E-domain of Staphylococcal protein A and an antibody Fv-fragment. Biochemistry 39, 26–36.

55.	Nelson, D. L., Kurman, C. C., and Serbousek, D. E. (1994) 51Cr release assay of antibody-dependent cell-mediated cytotoxicity (ADCC); In Current Protocols in Immunology, Vol. 2. Coligan, J. E., Kruisbeek, A. M., Margulies, D. H., Shevach, E. M., and Strober, W., eds. John Wiley & Sons, New York, NY, pp. 7.27.1–7.27.8.

56.	Donohue, J. H. and Rosenberg, S. A. (1983) The fate of interleukin-2 after in vivo administration. J. Immunol. 130, 2203–2208.

57.	Kendra, K., Gan, J., Ricci, M., et al. (1999) Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice. Cancer Immunol. Immunother. 48, 219–229.

58.	Harvill, E. T., Fleming, J. M., and Morrison, S. L. (1996) In vivo properties of an IgG3-IL-2 fusion protein. A general strategy for immune potentiation. J. Immunol. 157, 3165–3170.

59.	Becker, J. C., Pancook, J. D., Gillies, S. D., Mendelsohn, J., and Reisfeld, R. A. (1996) Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by anti-body-interleukin 2 fusion proteins. Proc. Natl. Acad. Sci. USA 93, 2702–2707.

60.	Lode, H. N., Xiang, R., Dreier, T., Varki, N. M., Gillies, S. D., and Reisfeld, R. A. (1998) Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 91, 1706–1715.

61.	Becker, J. C., Varki, N., Gillies, S. D., Furukawa, K., and Reisfeld, R. A. (1996) An anti-body-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc. Natl. Acad. Sci. USA 93, 7826–7831.

62.	Sabzevari, H., Gillies, S. D., Mueller, B. M., Pancook, J. D., and Reisfeld, R. A. (1994) A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc. Natl. Acad. Sci. USA 91, 9626–9630.

63.	Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Plasmid vectors. In: Molecular Cloning: A Laboratory Manual. 2nd Ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, pp. 1.1–1.110.

64.	Chen, T. T., Tao, M. H., and Levy, R. (1994) Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. J. Immunol. 153, 4775–4787.

65.	Harlow, E. and Lane, D. (1989) Bacterial cell wall proteins that bind antibodies. In: Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, pp. 615–623.

66.	Harvill, E. T. and Morrison, S. L. (1996) An IgG3-IL-2 fusion protein has higher affinity than hrIL-2 for the IL-2R alpha subunit: real time measurement of ligand binding. Mol. Immunol. 33, 1007–1014.

67.	Liu, Z., Gurlo, T., and von Grafenstein, H. (2000) Cell-ELISA using beta-galactosidase conjugated antibodies. J. Immunol. Methods 234, P153–167.

68.	McKenzie, A. N. J. and Zurawski, G. (1994) Measurement of Interleukin-13. In: Current Protocols in Immunology, Vol. 1. Coligan, J. E., Kruisbeek, A. M., Margulies, D. H., Shevach, E. M., and Strober, W., eds. John Wiley & Sons, New York, NY, pp. 6.18.1–6.18.5.

69.	Gieni, R. S., Li, Y., and HayGlass, K. T. (1995) Comparison of [3H]-thymidine incorporation with MTT-and MTS-based bioassays for human and murine IL-2 and IL-4 analysis. Tetrazolium assays provide markedly enhanced sensitivity. J. Immunol. Methods 187, 85–93.

Comments (Loading...)

Post comment/View all comments